AbCellera Biologics Inc. ABCL Research fees — Total Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbCellera Biologics Inc.'s research fees — total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbCellera Biologics Inc.'s research fees — total revenue?
- AbCellera Biologics Inc. (ABCL) reported research fees — total revenue of $8.12M in Q1 2026.
- How has AbCellera Biologics Inc.'s research fees — total revenue changed year-over-year?
- AbCellera Biologics Inc.'s research fees — total revenue increased by 99.7% year-over-year, from $4.07M to $8.12M.
- What is the long-term trend for AbCellera Biologics Inc.'s research fees — total revenue?
- Over 4 years (2021 to 2025), AbCellera Biologics Inc.'s research fees — total revenue has grown at a 9.3% compound annual growth rate (CAGR), from $19.08M to $27.21M.
- What does research fees — total revenue mean?
- This metric represents the total revenue generated from research and development service fees charged to partners for antibody discovery projects. It reflects the company's ability to monetize its proprietary technology platform through upfront payments and service-based engagements before clinical milestones are reached. Tracking this revenue stream provides insight into the demand for the company's early-stage discovery services and the health of its collaborative pipeline.